Drugs / MK-1064
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02549027 | Nov 2009 → Apr 2010 | — | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 1 | NCT02549014 | Jul → Sep 2009 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1064 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02549014 ↗ |
| Modality | Small molecule | — CHEMBL3338866 ↗ |
| Route | Oral | “single oral doses of MK-1064 5 mg” NCT02549014 ↗ |